A drug used to treat allergic reactions.
| Member | Definition | Class |
|---|
| (S)-carbinoxamine maleate | The maleic acid salt of (S)-carbinoxamine. | (S)-carbinoxamine maleate |
| 5,4'-dihydroxy-7,3'-dimethoxyflavone | A dimethoxyflavone that is luteolin in which the hydroxy groups at positions 7 and 3' are replaced by methoxy groups. | velutin |
| abt-737 | A biphenyl that is 4-chloro-1,1'-biphenyl substituted by a (4-{4-[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene-1-sulfonyl)carbamoyl]phenyl}piperazin-1-yl)methyl group at position 2'. It is a BH3-mimetic drug which targets the anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, and induces apoptosis in cancer cells. | ABT-737 |
| alcaftadine | An imidazobenzazepine that is 6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine substituted at position 3 by a formyl group and at position 11 by a 1-methylpiperidin-4-ylidene group. An antihistamine used for treatment of allergic conjunctivitis. | alcaftadine |
| amlexanox | A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position. | amlexanox |
| astemizole | A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position. | astemizole |
| azatadine | A benzo[5,6]cyclohepta[1,2-b]pyridine having a 1-methylpiperidin-4-ylidene group at the 11-position. | azatadine |
| azelastine | A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. | azelastine |
| azelastine hydrochloride | The hydrochloride salt of azelastine. | azelastine hydrochloride |
| brompheniramine | Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis. | brompheniramine |
| brompheniramine maleate | The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis. | brompheniramine maleate |
| capsiate | A carboxylic ester obtained by formal condensation of the carboxy group of (6E)-8-methylnon-6-enoic acid with the benzylic hydroxy group of vanillyl alcohol. A non-pungent analogue of capsaicin with a similar biological profile. | capsiate |
| carbinoxamine | An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease. | carbinoxamine |
| carbinoxamine maleate | The maleic acid salt of carbinoxamine. An ethanolamine-type antihistamine, used for treating hay fever, as well as mild cases of Parkinson's disease. | carbinoxamine maleate |
| cetirizine | A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively. | cetirizine |
| chlorpheniramine | A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma. | chlorphenamine |
| cinnarizine | | cinnarizine |
| clemastine | 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions. | clemastine |
| clemastine fumarate | The fumaric acid salt of clemastine. An antihistamine with antimuscarinic and moderate sedative properties, it is used for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions. | clemastine fumarate |
| cyproheptadine | The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia. | cyproheptadine |
| davidigenin | A member of the class of dihydrochalcones that is dihydrochalcone substituted by hydroxy groups at positions 4, 2', and 4' respectively. | davidigenin |
| desloratadine | Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness. | desloratadine |
| dexbrompheniramine | The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis. | dexbrompheniramine |
| dexbrompheniramine maleate | The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis. | dexbrompheniramine maleate |
| diphenhydramine | An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug. | diphenhydramine |
| diphenhydramine hydrochloride | The hydrochloride salt of diphenhydramine. | diphenhydramine hydrochloride |
| doxylamine | | doxylamine |
| emedastine | 1-Methyl-1,4-diazepane in which the hydrogen attached to the nitrogen at position 4 is substituted by a 1-(2-ethoxyethyl)-1H-benzimidazol-2-yl group. A relatively selective histamine H1 antagonist, it is used as the difumatate salt for allergic rhinitis, urticaria, and pruritic skin disorders, and in eyedrops for the symptomatic relief of allergic conjuntivitis. | emedastine |
| epinastine | A benzazepine that is 6,11-dihydro-5H-dibenzo[b,e]azepine in which the azepine ring is fused to the e side of 4,5-dihydro-1H-imidazol-2-amine. | epinastine |
| fexofenadine | A piperidine-based anti-histamine compound. | fexofenadine |
| fluticasone | A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis. | fluticasone |
| fluticasone furoate | A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a 2-furoyl substituent at position 17. Used in combination with vilanterol trifenate for treatment of bronchospasm associated with chronic obstructive pulmonary disease. | fluticasone furoate |
| fluticasone propionate | A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity. | fluticasone propionate |
| ginsenoside m1 | A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 20 has been converted to the corresponding beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position. | ginsenoside C-K |
| glycyrrhetyl 3-monoglucuronide | A triterpenoid saponin that is the 3-O-beta-glucuronide of glycyrrhetic acid. It is a metabolite of glycyrrhizin contained in licorice and potentially a causative agent in the pathogenesis of pseudoaldosteronism. | glycyrrhetic acid 3-O-glucuronide |
| hydrangenol | A member of the class of dihydroisocoumarins that is 3,4-dihydroisocoumarin substituted by a hydroxy group at position 8 and a 4-hydroxyphenyl group at position 3. It has been isolated from the roots of Scorzonera judaica and exhibits anti-allergic activity. | hydrangenol |
| jaceosidin | A trihydroxyflavone that is flavone with hydroxy groups at positions 5, 7 and 4' and methoxy groups at positions 3' and 6. Isolated from Salvia tomentosa and Artemisia asiatica, it exhibits anti-allergic, anti-inflammatory and apoptosis inducing activties. | jaceosidin |
| loratadine | A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders. | loratadine |
| methapyrilene | A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group. | methapyrilene |
| methapyrilene hydrochloride | A hydrochloride that is the monohydrochloride salt of methapyrilene. | methapyrilene hydrochloride |
| mometasone furoate | | mometasone furoate |
| myricitrin | A glycosyloxyflavone that consists of myricetin attached to a alpha-L-rhamnopyranosyl residue at position 3 via a glycosidic linkage. Isolated from Myrica cerifera, it exhibits anti-allergic activity. | myricitrin |
| naringenin chalcone | A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 2' ,4, 4', and 6' respectively. | 2',4,4',6'-tetrahydroxychalcone |
| nedocromil | | nedocromil |
| oxatomide | A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug. | oxatomide |
| petasin | An enoate ester obtained by formal condensation of the carboxy group of angelic acid with the hydroxy group of (1R,2R,7S,8aR)-1,8a-dimethyl-6-oxo-7-(prop-1-en-2-yl)-1,2,3,4,6,7,8,8a-octahydronaphthalen-2-ol. | petasin |
| promethazine | A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety. | promethazine |
| promethazine hydrochloride | The hydrochloride salt of promethazine. | promethazine hydrochloride |
| rhapontin | A rhaponticin in which the double bond adopts a trans-configuration. It possesses a range of pharmacological activities including antitumour, antiinflammatory, antilipemic and neuroprotective activities. | trans-rhaponticin |
| rhodiocyanoside a | A cyanogenic glycoside that is (2Z)-2-methylbut-2-enenitrile attached to a beta-D-glucopyranosyloxy at position 4. Isolated from Rhodiola quadrifida, it exhibits anti-allergic activity. | rhodiocyanoside A |
| rottlerin | A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis. | rottlerin |
| sappanchalcone | A member of the class of chalcones that consists of trans-chalcone substituted by hydroxy groups at positions 3, 4 and 4' and a methoxy group at position 2'. Isolated from Caesalpinia sappan, it exhibits neuroprotective and cytoprotective activity. | sappanchalcone |
| scoparone | A member of the class of coumarins that is esculetin in which the two hydroxy groups at positions 6 and 7 are replaced by methoxy groups. It is a major constituent of the Chinese herbal medicine Yin Chen Hao, and exhibits a variety of pharmacological activities such as anti-inflammatory, anti-allergic, and anti-tumor activities. | scoparone |
| secoxyloganin | A secoiridoid glycoside that is [(2R,3R,4S)-2-hydroxy-5-(methoxycarbonyl)-3-vinyl-3,4-dihydro-2H-pyran-4-yl]acetic acid in which the anometric hydroxy group has been converted to the corresponding beta-D-glucoside. It has been isolated from several plant species and exhibits antioxidant and anti-allergic properties. | secoxyloganin |
| tau 284 | An organosulfonate salt obtained by combining equimolar amounts of bepotastine and benzenesulfonic acid. A topical, selective and non-sedating histamine (H1) receptor antagonist used for treatment of itching associated with allergic conjunctivitis. | bepotastine besylate |
| tixocortol pivalate | The pivalate thioester of tixocortol. | tixocortol pivalate |
| tranilast | An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group. | tranilast |
| triamcinolone | A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections. | triamcinolone |
| triamcinolone acetonide | A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections. | triamcinolone acetonide |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 1 | 1 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| 67.9K protein | Vaccinia virus | Potency | 9.9446 | 2 | 7 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 30.4099 | 3 | 20 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 29.7528 | 2 | 5 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 29.3719 | 1 | 9 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 40.8708 | 1 | 2 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 12.9676 | 1 | 2 |
| AR protein | Homo sapiens (human) | Potency | 19.3707 | 11 | 139 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 9.1139 | 2 | 8 |
| arylsulfatase A | Homo sapiens (human) | Potency | 10.0864 | 1 | 8 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 15.4148 | 4 | 13 |
| Ataxin-2 | Homo sapiens (human) | Potency | 22.3235 | 2 | 19 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 21.9513 | 3 | 12 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 24.5963 | 2 | 18 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 9.0102 | 1 | 2 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 16.0575 | 1 | 6 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 20.4870 | 2 | 12 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 51.4880 | 1 | 9 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 29.3211 | 1 | 8 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 26.0305 | 1 | 3 |
| caspase-3 | Homo sapiens (human) | Potency | 29.3211 | 1 | 8 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 26.0305 | 1 | 3 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 33.2681 | 2 | 23 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 16.1708 | 2 | 9 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 26.5398 | 1 | 9 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 32.0016 | 2 | 6 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 80.7254 | 2 | 10 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 30.6332 | 2 | 7 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 29.2215 | 2 | 5 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 22.5358 | 2 | 2 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 55.5278 | 1 | 2 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 19.1079 | 2 | 9 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 14.3819 | 1 | 3 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 17.6055 | 1 | 4 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 22.5358 | 2 | 2 |
| chaperonin GroEL | Methanococcus maripaludis S2 | Potency | 100.0000 | 1 | 1 |
| chaperonin-containing TCP-1 beta subunit homolog | Homo sapiens (human) | Potency | 52.4870 | 1 | 2 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 42.5520 | 2 | 13 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 9.7835 | 1 | 8 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 19.0531 | 1 | 5 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 12.6406 | 1 | 8 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 5.6564 | 1 | 17 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 7.7968 | 1 | 13 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 9.0237 | 2 | 23 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 10.3906 | 2 | 19 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 18.3982 | 1 | 15 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 5.1773 | 2 | 7 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 14.6892 | 1 | 1 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 10.0635 | 1 | 3 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 16.1936 | 1 | 2 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 32.4648 | 1 | 2 |
| DNA polymerase III, partial | Bacillus subtilis | Potency | 18.8876 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 51.8960 | 2 | 9 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 23.9064 | 1 | 4 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 14.5924 | 1 | 2 |
| endonuclease IV | Escherichia coli | Potency | 25.9485 | 1 | 2 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 7.0795 | 1 | 1 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 7.0795 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 26.6801 | 10 | 99 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 34.3266 | 3 | 20 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 26.2525 | 9 | 98 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 25.9620 | 2 | 39 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 16.4007 | 4 | 27 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 28.0179 | 3 | 14 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 21.3533 | 2 | 9 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 26.8224 | 1 | 8 |
| G | Vesicular stomatitis virus | Potency | 12.6406 | 1 | 8 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 9.0644 | 1 | 12 |
| geminin | Homo sapiens (human) | Potency | 14.7728 | 4 | 28 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 16.2024 | 3 | 47 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 15.1646 | 1 | 7 |
| GLS protein | Homo sapiens (human) | Potency | 16.0889 | 2 | 10 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 24.4409 | 1 | 4 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 15.3753 | 4 | 42 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 36.6860 | 1 | 7 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 3.6626 | 1 | 1 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 34.1729 | 2 | 3 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 12.7233 | 2 | 4 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 30.8588 | 2 | 12 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 16.9232 | 2 | 47 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 23.9017 | 1 | 5 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 0.4088 | 2 | 2 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 65.0539 | 2 | 13 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 46.5909 | 1 | 2 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 12.6406 | 1 | 8 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 34.0218 | 1 | 5 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 32.9838 | 1 | 2 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 25.9879 | 2 | 12 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 10.5164 | 2 | 16 |
| IDH1 | Homo sapiens (human) | Potency | 12.9596 | 1 | 7 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 3.6626 | 1 | 1 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 12.6406 | 1 | 16 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 4.5346 | 1 | 10 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 18.0707 | 1 | 3 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 18.0707 | 1 | 3 |
| Interferon beta | Homo sapiens (human) | Potency | 17.1455 | 3 | 22 |
| isocitrate dehydrogenase 1, partial | Homo sapiens (human) | Potency | 31.5042 | 2 | 3 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 13.6062 | 2 | 22 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 8.4919 | 1 | 6 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 5.5602 | 4 | 9 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 28.1147 | 3 | 7 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 29.6902 | 1 | 8 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 16.6722 | 2 | 18 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 15.1337 | 2 | 9 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 5.0811 | 2 | 15 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 14.0353 | 1 | 5 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 32.2734 | 1 | 3 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 32.2734 | 1 | 3 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 15.4508 | 3 | 9 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 9.9968 | 2 | 6 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 15.1475 | 1 | 5 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 11.9938 | 1 | 5 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 24.7551 | 3 | 25 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 7.4000 | 2 | 4 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 24.1130 | 2 | 9 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 12.5232 | 2 | 16 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 5.1591 | 1 | 4 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 31.4758 | 3 | 28 |
| Ornithine decarboxylase | Rattus norvegicus (Norway rat) | Potency | 9.9888 | 1 | 2 |
| P53 | Homo sapiens (human) | Potency | 70.7946 | 1 | 1 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 57.4570 | 1 | 2 |
| Parkin | Homo sapiens (human) | Potency | 21.9913 | 3 | 3 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 45.6298 | 2 | 4 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 23.7704 | 2 | 11 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 64.1571 | 1 | 8 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 25.7217 | 5 | 16 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 38.9543 | 5 | 24 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 54.3385 | 2 | 7 |
| PINK1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 7.1178 | 1 | 4 |
| polyprotein | Zika virus | Potency | 26.8224 | 1 | 8 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 7.0795 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 15.9249 | 1 | 16 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 9.6667 | 1 | 21 |
| PPM1D protein | Homo sapiens (human) | Potency | 20.2299 | 1 | 6 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 18.4359 | 3 | 29 |
| progesterone receptor | Homo sapiens (human) | Potency | 16.5040 | 3 | 27 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 9.2834 | 4 | 5 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 14.1254 | 2 | 2 |
| pyruvate kinase PKM isoform b | Homo sapiens (human) | Potency | 9.9889 | 2 | 4 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 89.1251 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 19.3656 | 2 | 26 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 33.5974 | 1 | 6 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 16.7587 | 1 | 7 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 28.4606 | 3 | 54 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 23.6659 | 3 | 21 |
| serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 16.3974 | 2 | 3 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 19.6952 | 2 | 4 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 37.6858 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 25.7412 | 2 | 13 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 25.7412 | 2 | 13 |
| Smad3 | Homo sapiens (human) | Potency | 17.8526 | 1 | 2 |
| snurportin-1 | Homo sapiens (human) | Potency | 3.6626 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 21.4414 | 2 | 13 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 14.6075 | 1 | 13 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 5.5987 | 1 | 3 |
| TDP1 protein | Homo sapiens (human) | Potency | 17.3950 | 2 | 58 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 47.3936 | 1 | 2 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 18.6080 | 3 | 17 |
| Thrombopoietin | Homo sapiens (human) | Potency | 10.0039 | 2 | 8 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 24.9970 | 3 | 51 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 3.5481 | 1 | 1 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 25.2235 | 6 | 27 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 14.8230 | 2 | 2 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 24.3194 | 1 | 3 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 10.0635 | 1 | 3 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 7.1178 | 1 | 4 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 7.1178 | 1 | 4 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 49.9224 | 3 | 15 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 18.9259 | 2 | 31 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 30.5134 | 3 | 13 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 47.1051 | 1 | 10 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 36.6860 | 1 | 7 |